Effects of sibutramine plus verapamil sustained release/trandolapril combination on blood pressure and metabolic variables in obese hypertensive patients

Bibliography

• Balkau B, Deanfield JE, Despres JP, et al. International Day for the Evaluation of Abdominal Obesity (IDEA): a study of waist circumference, cardiovascular disease, and diabetes mellitus in 168,000 primary care patients in 63 countries. Circulation 2007;116:1942-51
   PubMed Web of Science ®Google Scholar
• James WP, Astrup A, Finer N, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 2000;356:2119-25
   PubMed Web of Science ®Google Scholar
• Schneider R, Golzman B, Turkot S, et al. Effect of weight loss on blood pressure, arterial compliance, and insulin resistance in normotensive obese subjects. Am J Med Sci 2005;330:157-60
   PubMedGoogle Scholar
• Sjostrom CD, Peltonen M, Sjostrom L. Blood pressure and pulse pressure during long-term weight loss in the obese: the Swedish Obese Subjects (SOS) Intervention Study. Obes Res 2001;9:188-95
   PubMedGoogle Scholar
• Filippatos TD, Kiortsis DN, Liberopoulos EN, et al. Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study. Curr Med Res Opin 2005;21:1997-2006
   PubMed Web of Science ®Google Scholar
• Liberopoulos EN, Mikhailidis DP, Elisaf MS. Diagnosis and management of the metabolic syndrome in obesity. Obes Rev 2005;6:283-96
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Kiortsis DN, Liberopoulos EN, et al. A review of the metabolic effects of sibutramine. Curr Med Res Opin 2005;21:457-68
   PubMed Web of Science ®Google Scholar
• Florentin M, Liberopoulos EN, Elisaf MS. Sibutramine-associated adverse effects: a practical guide for its safe use. Obes Rev 2007 [E-pub ahead of print]
   PubMedGoogle Scholar
• Rucker D, Padwal R, Li SK, et al. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007;335:1194-9
   PubMed Web of Science ®Google Scholar
• Dooley M, Goa KL. Fixed combination verapamil SR/trandolapril. Drugs 1998;56:837-44
   PubMedGoogle Scholar
• Karlberg BE, Andrup M, Oden A. Efficacy and safety of a new long-acting drug combination, trandolapril/verapamil as compared to monotherapy in primary hypertension. Swedish TARKA trialists. Blood Pressure 2000;9:140-5
   PubMed Web of Science ®Google Scholar
• Holzgreve H, Nakov R, Beck K, Janka HU. Antihypertensive therapy with verapamil SR plus trandolapril versus atenolol plus chlorthalidone on glycemic control. Am J Hypertens 2003;16:381-6
   PubMed Web of Science ®Google Scholar
• Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-87
   PubMed Web of Science ®Google Scholar
• Bairaktari ET, Seferiadis KI, Elisaf MS. Evaluation of methods for the measurement of low-density lipoprotein cholesterol. J Cardiovasc Pharmacol Ther 2005;10:45-54
   PubMed Web of Science ®Google Scholar
• Gazi I, Lourida ES, Filippatos T, et al. Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. Clin Chem 2005;51:2264-73
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Liberopoulos EN, Kostapanos M, et al. The effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndrome. Diabetes Obes Metab 2007;10:476-83
   PubMedGoogle Scholar
• Miida T, Miyazaki O, Nakamura Y, et al. Analytical performance of a sandwich enzyme immunoassay for pre beta 1-HDL in stabilized plasma. J Lipid Res 2003;44:645-50
   PubMedGoogle Scholar
• Kostapanos MS, Derdemezis CS, Filippatos TD, et al. Effect of rosuvastatin treatment on plasma visfatin levels in patients with primary hyperlipidemia. Eur J Pharmacol 2008;578:249-52
   PubMed Web of Science ®Google Scholar
• Arterburn DE, Crane PK, Veenstra DL. The efficacy and safety of sibutramine for weight loss: a systematic review. Arch Intern Med 2004;164:994-1003
   PubMed Web of Science ®Google Scholar
• Bakris G, Sica D, Ram V, et al. A comparative trial of controlled-onset, extended-release verapamil, enalapril, and losartan on blood pressure and heart rate changes. Am J Hypertens 2002;15:53-7
   PubMed Web of Science ®Google Scholar
• Effects of verapamil SR, trandolapril, and their fixed combination on 24-h blood pressure: the Veratran Study. Am J Hypertens 1997;10:492-9
   PubMedGoogle Scholar
• Sramek JJ, Leibowitz MT, Weinstein SP, et al. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial. J Human Hypertens 2002;16:13-9
   PubMed Web of Science ®Google Scholar
• McMahon FG, Weinstein SP, Rowe E, et al. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors. J Human Hypertens 2002;16:5-11
   PubMed Web of Science ®Google Scholar
• Ersoz HO, Ukinc K, Baykan M, et al. Effect of low-dose metoprolol in combination with sibutramine therapy in normotensive obese patients: a randomized controlled study. Int J Obes Relat Metab Disord 2004;28:378-83
   PubMed Web of Science ®Google Scholar
• Aksoyek S, Ozer N, Aytemir K, Kes S. Verapamil SR and trandolapril combination therapy is safe and effective in hypertensive patients with metabolic disorders. Int J Clin Pract 2001;55:5-9
   PubMedGoogle Scholar
• Schneider M, Lerch M, Papiri M, et al. Metabolic neutrality of combined verapamil–trandolapril treatment in contrast to beta-blocker-low-dose chlortalidone treatment in hypertensive type 2 diabetes. J Hypertens 1996;14:669-77
   PubMed Web of Science ®Google Scholar
• Bakris G, Molitch M, Hewkin A, et al. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care 2006;29:2592-7
   PubMed Web of Science ®Google Scholar
• Athyros VG, Elisaf M, Papageorgiou AA, et al. Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Am J Kidney Dis 2004;43:589-99
   PubMed Web of Science ®Google Scholar
• Fernandez R, Puig JG, Rodriguez-Perez JC, et al. Effect of two antihypertensive combinations on metabolic control in type-2 diabetic hypertensive patients with albuminuria: a randomised, double-blind study. J Human Hypertens 2001;15:849-56
   PubMed Web of Science ®Google Scholar
• Sabuncu T, Nazligul Y, Karaoglanoglu M, et al. The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis. Rom J Gastroenterol 2003;12:189-92
   PubMedGoogle Scholar
• Diakou MC, Liberopoulos EN, Mikhailidis DP, et al. Pharmacological treatment of non-alcoholic steatohepatitis: the current evidence. Scand J Gastroenterol 2007;42:139-47
   PubMed Web of Science ®Google Scholar
• Athyros VG, Mikhailidis DP, Didangelos TP, et al. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin 2006;22:873-83
   PubMed Web of Science ®Google Scholar
• Cifkova R, Nakov R, Novozamska E, et al. Evaluation of the effects of fixed combinations of sustained-release verapamil/trandolapril versus captopril/hydrochlorothiazide on metabolic and electrolyte parameters in patients with essential hypertension. J Human Hypertens 2000;14:347-54
   PubMedGoogle Scholar
• Quinones-Galvan A, Pucciarelli A, Ciociaro D, et al. Metabolic effects of combined antihypertensive treatment in patients with essential hypertension. J Cardiovasc Pharmacol 2002;40:916-21
   PubMedGoogle Scholar
• Gokcel A, Gumurdulu Y, Karakose H, et al. Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity. Diabetes Obes Metab 2002;4:49-55
   PubMed Web of Science ®Google Scholar
• St-Pierre AC, Cantin B, Dagenais GR, et al. Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol 2005;25:553-9
   PubMed Web of Science ®Google Scholar
• Gardner CD, Fortmann SP, Krauss RM. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA 1996;276:875-81
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Gazi IF, Liberopoulos EN, et al. The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome. Atherosclerosis 2007;193:428-37
   PubMed Web of Science ®Google Scholar
• Ridker PM. High-sensitivity C-reactive protein and cardiovascular risk: rationale for screening and primary prevention. Am J Cardiol 2003;92:17K-22K
   PubMed Web of Science ®Google Scholar
• De Maat MP, Kluft C, Gram J, Jespersen J. Angiotensin-converting enzyme inhibitor trandolapril does not affect C-reactive protein levels in myocardial infarction patients. Circulation 2003;108:e113
   Google Scholar
• Ichihara A, Hayashi M, Kaneshiro Y, et al. Low doses of losartan and trandolapril improve arterial stiffness in hemodialysis patients. Am J Kidney Dis 2005;45:866-74
   PubMed Web of Science ®Google Scholar
• Valsamakis G, Mcternan PG, Chetty R, et al. Modest weight loss and reduction in waist circumference after medical treatment are associated with favorable changes in serum adipocytokines. Metabolism 2004;53:430-4
   PubMed Web of Science ®Google Scholar
• Shechter M, Beigel R, Freimark D, et al. Short-term sibutramine therapy is associated with weight loss and improved endothelial function in obese patients with coronary artery disease. Am J Cardiol 2006;97:1650-3
   PubMed Web of Science ®Google Scholar
• Luk T, Malam Z, Marshall JC. Pre-B cell colony-enhancing factor (PBEF)/visfatin: a novel mediator of innate immunity. J Leukoc Biol 2008;83:804-16
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Derdemezis CS, Gazi IF, et al. Increased plasma visfatin levels in subjects with the metabolic syndrome. Eur J Clin Invest 2008;38:71-2
   PubMed Web of Science ®Google Scholar
• Tilg H, Moschen AR. Role of adiponectin and PBEF/visfatin as regulators of inflammation: involvement in obesity-associated diseases. Clin Sci (Lond) 2008;114:275-88
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Derdemezis CS, Kiortsis DN, et al. Increased plasma levels of visfatin/pre-B cell colony-enhancing factor in obese and overweight patients with metabolic syndrome. J Endocrinol Invest 2007;30:323-6
   PubMed Web of Science ®Google Scholar
• Haider DG, Schindler K, Schaller G, et al. Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. J Clin Endocrinol Metab 2006;91:1578-81
   PubMed Web of Science ®Google Scholar
• Manco M, Fernandez-Real JM, Equitani F, et al. Effect of massive weight loss on inflammatory adipocytokines and the innate immune system in morbidly obese women. J Clin Endocrinol Metab 2007;92:483-90
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Derdemezis CS, Georgoula M, et al. Fenofibrate and orlistat, alone or in combination, do not alter plasma visfatin levels in subjects with metabolic syndrome. J Med Sci Res 2007;2:9-10
   Google Scholar
• Papadakis JA, Ganotakis ES, Jagroop IA, et al. Effect of hypertension and its treatment on lipid, lipoprotein(a), fibrinogen, and bilirubin levels in patients referred for dyslipidemia. Am J Hypertens 1999;12:673-81
   PubMed Web of Science ®Google Scholar